The Utility of Patency Capsule in Patients With Crohn's Disease.

Background: Video capsule retention is a complication that can have serious consequences in patients with Crohn's disease (CD). The patency capsule was developed to detect small bowel strictures. The usefulness of patency capsules in patients who do not have evidence of small bowel disease on imaging is uncertain.

What mechanisms lead to the endurance of health and social care integration? A multiple case study in Italy.

Background: The rising complexity of the population's needs has made health and social care integration a priority for the future. Despite the presence of supporting policies and funding, the number of successful experiences that endure over time is limited.

Objective: This work aims to investigate how health and social care integration occur and identify factors facilitating its endurance.

Dynamical critical behavior on the Nishimori point of frustrated Ising models.

By considering the quench dynamics of two-dimensional frustrated Ising models through numerical simulations, we investigate the dynamical critical behavior on the multicritical Nishimori point (NP). We calculate several dynamical critical exponents, namely, the relaxation exponent z_{c}, the autocorrelation exponent λ_{c}, and the persistence exponent θ_{c}, after a quench from the high temperature phase to the NP. We confirm their universality with respect to the lattice geometry and bond distribution.

Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.

Background And Aims: Upadacitinib is an oral selective Janus kinase (JAK) inhibitor approved in the United States for ulcerative colitis (UC) and Crohn's disease (CD). However, data regarding its use following prior treatment with the JAK inhibitor tofacitinib is sparse. As such, we aimed to evaluate the effectiveness of upadacitinib therapy following tofacitinib exposure.

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study.

Background: Metformin exerts anti-inflammatory properties through a positive effect on oxidative stress, gut barrier integrity, and the gut microbiota. Our aim was to evaluate the influence of metformin on inflammatory bowel disease (IBD) outcomes in patients with type 2 diabetes mellitus (T2DM).

Methods: We conducted a retrospective cohort study using the TriNetX database in patients with IBD and T2DM who initiated metformin vs oral hypoglycemics or insulin (control cohort) between August 31, 2002, and August 31, 2022.